Lexaria Bioscience Corp. (LEXX)

$2.9

+0.04 (+1.40%)
Rating:
Recommendation:
-
Symbol LEXX
Price $2.9
Beta 1.061
Volume Avg. 0.02M
Market Cap 17.258M
Shares () -
52 Week Range 1.8-5.4
1y Target Est -
DCF Unlevered LEXX DCF ->
DCF Levered LEXX LDCF ->
ROE -57.63% Strong Sell
ROA -74.06% Strong Sell
Operating Margin -
Debt / Equity 2.53% Neutral
P/E -2.24 Sell
P/B 2.15 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LEXX news


Healthcare
Biotechnology
NASDAQ Capital Market

Lexaria Bioscience Corp. operates as a biotechnology company. It operates through two segments, Intellectual Property Licensing and B2B Production. The company develops and out-licenses its DehydraTECH technology that improves the delivery of bioactive compounds that promotes healthy ingestion methods, lowers overall dosing, and higher effectiveness in active molecule delivery. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and various cannabinoids. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 27 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.